This proposal is based on the fact that oncogenes that confer a survival advantage to the HSC and are frequently mutated in human AML, such as RAS and FLT3, are only capable of inducing myeloproliferative neoplasms in mouse models, but not the transition to AML [75,76,77]. This evidence concerns the gene FLT3 and acute myeloid leukemia.